Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582395 · ClinicalTrials.gov registry record · Phase 3
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 580
- Enrollment target
NCT05582395 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 580 participants.
The verdict
NCT05582395, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 580 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Interventions
- OTHER Placebo
- DRUG Mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2025-10-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05582395
The ClinicalTrials.gov registry entry for NCT05582395 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05582395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05582395 about?
NCT05582395 is a clinical study titled "A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy". The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
What is the current status of trial NCT05582395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2022-12-14. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT05582395?
The interventions under investigation include: Placebo (OTHER), Mavacamten (DRUG).
Who is sponsoring clinical trial NCT05582395?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.